PUBLICATIONS · 7494563
Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer.
Open original source → · Download preserved record
Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.
- Journal
- N Engl J Med
- Publication date
- 1996 Jan 4
- First author
- McGuire WP
Publication notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- citation
- N Engl J Med. 1996 Jan 4;334(1):50-1. doi: 10.1056/NEJM199601043340112.
- note
- Source null
- related pmid
- 7494573
- relationship
- Comment in
- citation
- N Engl J Med. 1996 May 9;334(19):1268-9; author reply 1270. doi: 10.1056/NEJM199605093341912.
- note
- Source null
- related pmid
- 8606729
- relationship
- Comment in
- citation
- N Engl J Med. 1996 May 9;334(19):1269; author reply 1270.
- note
- Source null
- related pmid
- 8606730
- relationship
- Comment in
Authors and identifiers
- name
- McGuire WP
- type
- Author
- name
- Hoskins WJ
- type
- Author
- name
- Brady MF
- type
- Author
- name
- Kucera PR
- type
- Author
- name
- Partridge EE
- type
- Author
- name
- Look KY
- type
- Author
- name
- Clarke-Pearson DL
- type
- Author
- name
- Davidson M
- type
- Author
Complete bibliographic record and source provenance
- authors
- name
- McGuire WP
- type
- Author
- name
- Hoskins WJ
- type
- Author
- name
- Brady MF
- type
- Author
- name
- Kucera PR
- type
- Author
- name
- Partridge EE
- type
- Author
- name
- Look KY
- type
- Author
- name
- Clarke-Pearson DL
- type
- Author
- name
- Davidson M
- type
- Author
- bibliography ids
- nci-bib-3e9f6fbebce03951a384d6a0
- book metadata
- content sha256
- c1c349777bc0b695ac062b1e338e779a8c8b7b82992f740bb1709b240e6b7d24
- document type
- citation
- dois
- 10.1056/NEJM199601043340101
- electronic publication date
- display
- Source null
- precision
- missing
- year
- Source null
- evidence scope
- bibliographic_metadata_only
- id
- pubmed:7494563
- immutable id
- pubmed:7494563@c1c349777bc0b695ac062b1e338e779a8c8b7b82992f740bb1709b240e6b7d24
- journal
- abbreviation
- N Engl J Med
- issn electronic
- Source null
- issn print
- 0028-4793
- issue
- 1
- name
- The New England journal of medicine
- nlm unique id
- 0255562
- pages
- 1-6
- volume
- 334
- languages
- eng
- notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- citation
- N Engl J Med. 1996 Jan 4;334(1):50-1. doi: 10.1056/NEJM199601043340112.
- note
- Source null
- related pmid
- 7494573
- relationship
- Comment in
- citation
- N Engl J Med. 1996 May 9;334(19):1268-9; author reply 1270. doi: 10.1056/NEJM199605093341912.
- note
- Source null
- related pmid
- 8606729
- relationship
- Comment in
- citation
- N Engl J Med. 1996 May 9;334(19):1269; author reply 1270.
- note
- Source null
- related pmid
- 8606730
- relationship
- Comment in
- outcomes validated
- false
- pmid
- 7494563
- provenance
- batch id
- 0195e80d659ca3142556
- provider
- NCBI PubMed ESummary
- record sha256
- 2004a8022abad3823cf13e3164693104c3f05ca2b4a071c6ef95e6ae77cc5c3c
- response sha256
- 021698996c455bb1930ebf197fc7e88fce61693e192449206cc5457c0644e062
- retrieved at
- 2026-09-09T23:45:16.849437+00:00
- publication date
- display
- 1996 Jan 4
- precision
- day
- year
- 1996
- publication types
- Clinical Trial
- Clinical Trial, Phase III
- Comparative Study
- Journal Article
- Randomized Controlled Trial
- Research Support, U.S. Gov't, P.H.S.
- record status
- PubMed - indexed for MEDLINE
- schema version
- 1.0
- source url
- https://pubmed.ncbi.nlm.nih.gov/7494563/
- title
- Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer.
Preserved source evidence · Not medical advice
Triangle